Teijin Pharma elects new President

Teijin Pharma, the core company of the Teijin Group’s healthcare business, has elected Akihisa Nabeshima as President

Nabeshima is currently corporate officer of the Teijin Group and Senior Executive Director of Teijin Pharma, as its next president.

Nabeshima will assume his new role on April 1. Hiroshi Uno, the current President, will assume the post of responsible for healthcare business of the Teijin Limited.

About the Teijin Group

Teijin is a technology-driven global group offering advanced solutions in the areas of sustainable transportation, information and electronics, safety and protection, environment and energy, and healthcare.

Its main fields of operation are high-performance fibers such as aramid, carbon fibers and composites, healthcare, films, resin and plastic processing, polyester fibers, products converting and IT.

The group has some 150 companies and around 16,000 employees spread out over 20 countries worldwide. It posted consolidated sales of around $7.4 bn and total assets of around $7.7 bn in the fiscal year ending March 31, 2016.

www.teijin.com

You may also like

Research & Development

Teijin gains exclusive rights in Japan to growth hormone deficiency treatment

Will develop Somavaratan for the treatment of paediatric growth hormone deficiency
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Regulatory

Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi

The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
Subscribe now